T-DM1 shows promise in treating unresectable locally advanced or metastatic HER2-positive breast cancer

Share :
Published: 10 Jan 2024
Views: 72
Rating:
Save
Dr Sara Hurvitz - University of Washington, Seattle, USA

Dr Sara Hurvitz speaks to ecancer about the HER2CLIMB-02 clinical trial, which is a randomised, double-blind phase 3 trial that investigated the efficacy of tucatinib and trastuzumab emtansine for the treatment of previously treated HER2-positive metastatic breast cancer.

The HER2CLIMB trial previously demonstrated that adding tucatinib to trastuzumab and capecitabine significantly improved progression-free survival, overall survival, as well as progression-free survival in patients with brain metastases.

The results from the HER2CLIMB-02 trial suggest that combining two HER2-targeted drugs, tucatinib and trastuzumab emtansine (T-DM1), may increase progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, when compared to T-DM1 alone.